FGEN Q4 2025 Earnings Call Summary

Kyntra Bio, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Q4 2025 Revenue: $1.3 million, down from $3.1 million in Q4 2024.
Full Year 2025 Revenue: $6.4 million, significantly lower than $29.6 million in 2024.
Operating Costs: Q4 2025 total operating expenses were $14.8 million, up from $10.3 million in Q4 2024. Full year operating expenses were $52.3 million, down from $180 million in 2024.
R&D Expenses: Q4 2025 R&D expenses were $7.3 million, slightly up from $6.9 million in Q4 2024. Full year R&D expenses were $23.5 million, down from $95.7 million in 2024.
Net Loss: Q4 2025 net loss was $14.6 million ($3.61 per share), compared to a net loss of $8.7 million ($2.15 per share) in Q4 2024. Full year net loss was $58.2 million ($14.40 per share), improved from a loss of $153.1 million ($38.26 per share) in 2024.
Cash Position: As of December 31, 2025, cash and equivalents totaled $109.4 million, providing a runway into 2028.

2. Strategic Updates and Business Highlights

Transformation: The company rebranded from FibroGen to Kyntra Bio to reflect its focus on oncology and rare diseases.
Clinical Development:
- FG-3246: A first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer (mCRPC). Phase 2 trials are underway, with promising interim results expected in 2026.
- Roxadustat: Submitted a phase 3 protocol for treating anemia in lower-risk myelodysplastic syndromes (MDS) and received Orphan Drug Designation. Feedback from the FDA is anticipated soon, with trial initiation targeted for the second half of 2026.
Market Opportunity: FG-3246 targets a significant market with an estimated annual value exceeding $5 billion in the U.S. alone.

3. Forward Guidance and Outlook

The company expects to report interim results from the FG-3246 phase 2 trial in 2026 and aims to finalize the phase 3 protocol for roxadustat, with a trial start anticipated in the same year.
The strategic focus remains on advancing clinical programs and maximizing cash runway to support ongoing development.

4. Bad News, Challenges, or Points of Concern

Declining Revenue: The significant drop in revenue year-over-year raises concerns about commercial viability and market traction.
Increased Losses: Despite a reduction in operating costs, the company continues to incur substantial losses, which could impact investor confidence.
Regulatory Delays: The timeline for FDA feedback on the roxadustat protocol may extend beyond initial expectations, potentially delaying the phase 3 trial start.

5. Notable Q&A Insights

Imaging and CD46 Opportunity: The company aims to position its CD46 PET imaging agent similarly to existing PSMA agents, with a focus on patient selection based on CD46 positivity.
Patient Selection Metrics: There is ongoing discussion about the use of SUV (Standardized Uptake Value) as a metric for patient selection, with varying opinions among key opinion leaders (KOLs) regarding its effectiveness.
Clinical Trial Design: The ongoing phase 2 trial for FG-3246 will focus on patients who have only progressed on one prior ARPI, differentiating it from the investigator-sponsored trial (IST) that included patients with more extensive prior treatments.

Overall, while Kyntra Bio has made significant strides in its clinical programs and financial management, challenges remain in terms of revenue generation and regulatory timelines. The upcoming clinical milestones will be critical for the company’s future trajectory.

FGEN — FibroGen, Inc.